GeneNews to exhibit ColonSentry™ at Family Medicine Forum 2008
TORONTO, CANADA (November 25, 2008):
GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will be exhibiting at the Family Medicine Forum 2008 being held at the Sheraton Centre in Toronto from November 27th to November 29th, 2008. GeneNews' exhibit, at booth No. 400, will feature the Company's lead product, ColonSentry™, the world's first blood-based test to determine a person's current risk for colorectal cancer.
"This event, which attracts more than 1500 family physicians and healthcare professionals, is the premier family medicine conference in Canada and the ideal audience to increase the awareness of ColonSentry™ in Canada," said Gailina Liew, Chief Operating Officer of GeneNews. "Building on the expanded roll out of ColonSentry™ at additional locations in the Greater Toronto Area last week, our exhibition at the Family Medicine Forum will further support our Canadian commercialization strategy as we plan to offer ColonSentry™ in other regions of Canada throughout 2009."
The Family Medicine Forum combines the Annual Scientific Assemblies of the College of Family Physicians of Canada (CFPC), the Ontario College of Family Physicians (OCFP), and the Annual Workshops of the CFPC's Sections of Teachers and Researchers. For additional information please visit http://fmf.cfpc.ca
Forward-Looking Statements
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
